Journal article

Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression

Edmund Lau, Patrick McCoy, Fairleigh Reeves, Ken Chow, Michael Clarkson, Edmond M Kwan, Kate Packwood, Helen Northen, Miao He, Zoya Kingsbury, Stefano Mangiola, Michael Kerger, Marc A Furrer, Helen Crowe, Anthony J Costello, David J McBride, Mark T Ross, Bernard Pope, Christopher M Hovens, Niall M Corcoran

Genome Medicine | BMC | Published : 2020

Abstract

BACKGROUND: DNA originating from degenerate tumour cells can be detected in the circulation in many tumour types, where it can be used as a marker of disease burden as well as to monitor treatment response. Although circulating tumour DNA (ctDNA) measurement has prognostic/predictive value in metastatic prostate cancer, its utility in localised disease is unknown. METHODS: We performed whole-genome sequencing of tumour-normal pairs in eight patients with clinically localised disease undergoing prostatectomy, identifying high confidence genomic aberrations. A bespoke DNA capture and amplification panel against the highest prevalence, highest confidence aberrations for each individual was desi..

View full abstract

Grants

Funding Acknowledgements

TAm-Seq analysis was funded by a philanthropic grant from Perpetual Trustees, Australia (PI NMC). Support for analysis was provided through the PRECEPT program grant, co-funded by Movember and the Australian Federal Government (PI NMC). BP was supported by a Victorian Health and Medical Research Fellowship from the Department of Health and Human Services in the State of Victoria. NMC was supported by a David Bickart Clinician Researcher Fellowship from the Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, and more recently by a Movember Distinguished Gentleman's Ride Clinician Scientist Award through the Prostate Cancer Foundation of Australia's Research Program.